Aptinyx Inc.

2.66-0.0300-1.12%Vol 144.32K1Y Perf -38.03%
Jul 23rd, 2021 16:00 DELAYED
BID2.65 ASK2.66
Open2.69 Previous Close2.69
Pre-Market- After-Market-
 - -  - -%
Target Price
9.71 
Analyst Rating
Strong Buy 1.00
Potential %
265.04 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap181.34M 
Earnings Rating
Buy
Price Range Ratio 52W %
8.63 
Earnings Date
12th Aug 2021

Today's Price Range

2.612.70

52W Range

2.306.47

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.14%
1 Month
-9.22%
3 Months
-2.21%
6 Months
-33.50%
1 Year
-38.03%
3 Years
-87.73%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APTX2.66-0.0300-1.12
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.21-0.22-4.76
Q04 2020-0.24-0.2016.67
Q03 2020-0.30-0.2420.00
Q02 2020-0.29-0.276.90
Q01 2020-0.33-0.34-3.03
Q04 2019-0.59-0.4130.51
Q03 2019-0.46-0.444.35
Q02 2019-0.52-0.3630.77
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.253.85Positive
9/2021 QR-0.283.45Positive
12/2021 FY-1.04-1.96Negative
12/2022 FY-1.04-11.83Negative
Next Report Date12th Aug 2021
Estimated EPS Next Report-0.25
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume144.32K
Shares Outstanding68.17M
Trades Count759
Dollar Volume1.74M
Avg. Volume820.77K
Avg. Weekly Volume210.58K
Avg. Monthly Volume645.99K
Avg. Quarterly Volume1.18M

Aptinyx Inc. (NASDAQ: APTX) stock closed at 2.66 per share at the end of the most recent trading day (a -1.12% change compared to the prior day closing price) with a volume of 144.88K shares and market capitalization of 181.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Aptinyx Inc. CEO is Norbert G. Riedel.

The one-year performance of Aptinyx Inc. stock is -38.03%, while year-to-date (YTD) performance is -23.12%. APTX stock has a five-year performance of %. Its 52-week range is between 2.3 and 6.47, which gives APTX stock a 52-week price range ratio of 8.63%

Aptinyx Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 1.20, a price-to-sale (PS) ratio of 144.92, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -35.37%, a ROC of -36.52% and a ROE of -36.52%. The company’s profit margin is -%, its EBITDA margin is -2 817.50%, and its revenue ttm is $1.26 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Aptinyx Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Aptinyx Inc.’s next earnings report date is 12th Aug 2021.

The consensus rating of Wall Street analysts for Aptinyx Inc. is Strong Buy (1), with a target price of $9.71, which is +265.04% compared to the current price. The earnings rating for Aptinyx Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptinyx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptinyx Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.46, ATR14 : 0.17, CCI20 : -93.40, Chaikin Money Flow : -0.12, MACD : -0.06, Money Flow Index : 32.93, ROC : -2.21, RSI : 43.27, STOCH (14,3) : 31.58, STOCH RSI : 0.31, UO : 54.12, Williams %R : -68.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptinyx Inc. in the last 12-months were: Andrew Kidd (Option Excercise at a value of $0), Ashish Khanna (Option Excercise at a value of $0), Norbert G. Riedel (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (100.00 %)
7 (87.50 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
1 (12.50 %)
1 (16.67 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.50
Moderate Buy
1.67

Aptinyx Inc.

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

CEO: Norbert G. Riedel

Telephone: +1 847 871-0377

Address: 909 Davis Street, Evanston 60201, IL, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

92%8%

Bearish Bullish

51%49%

Bearish Bullish

63%37%

News

Stocktwits